95 related articles for article (PubMed ID: 28959896)
1. Should clinically meaningful outcomes in cancer be based on individual survival rather than median overall survival?
Sacristán JA; Dilla T; Garrido P; Avendaño C; Cruz-Hernández JJ; Espinosa J; Comellas M; Lizán L
J Comp Eff Res; 2017 Sep; 6(6):491-495. PubMed ID: 28959896
[TBL] [Abstract][Full Text] [Related]
2. Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology.
Sacristán JA; Lizan L; Comellas M; Garrido P; Avendaño C; Cruz-Hernández JJ; Espinosa J; Dilla T
Adv Ther; 2016 Nov; 33(11):2059-2068. PubMed ID: 27718158
[TBL] [Abstract][Full Text] [Related]
3. Do oncologists believe new cancer drugs offer good value?
Nadler E; Eckert B; Neumann PJ
Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
[TBL] [Abstract][Full Text] [Related]
4. Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions.
Greenberg D; Hammerman A; Vinker S; Shani A; Yermiahu Y; Neumann PJ
Value Health; 2013; 16(5):842-7. PubMed ID: 23947979
[TBL] [Abstract][Full Text] [Related]
5. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
6. How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments.
Kozminski MA; Neumann PJ; Nadler ES; Jankovic A; Ubel PA
Med Decis Making; 2011; 31(3):380-5. PubMed ID: 21088130
[TBL] [Abstract][Full Text] [Related]
7. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
Daroudi R; Mirzania M; Zendehdel K
Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
[TBL] [Abstract][Full Text] [Related]
8. Cancer care, money, and the value of life: whose justice? Which rationality?
Sulmasy DP
J Clin Oncol; 2007 Jan; 25(2):217-22. PubMed ID: 17210943
[TBL] [Abstract][Full Text] [Related]
9. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival.
Ubel PA; Berry SR; Nadler E; Bell CM; Kozminski MA; Palmer JA; Evans WK; Strevel EL; Neumann PJ
Health Aff (Millwood); 2012 Apr; 31(4):709-17. PubMed ID: 22492887
[TBL] [Abstract][Full Text] [Related]
10. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.
Chabot I; Rocchi A
Value Health; 2010; 13(6):837-45. PubMed ID: 20561332
[TBL] [Abstract][Full Text] [Related]
11. Oncologists' Views on Using Value to Guide Cancer Treatment Decisions.
Gidwani-Marszowski R; Nevedal AL; Blayney DW; Patel M; Kelly PA; Timko C; Ramchandran K; Murrell SS; Asch SM
Value Health; 2018 Aug; 21(8):931-937. PubMed ID: 30098670
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis for clinical procedures in oncology.
Weinstein MC
Bull Cancer; 1980; 67(5):491-500. PubMed ID: 6783150
[TBL] [Abstract][Full Text] [Related]
13. Doctor-to-doctor communication of prognosis in metastatic cancer: a review of letters from medical oncologists to referring doctors.
Moth EB; Parry J; Stockler MR; Beale P; Blinman P; Della-Fiorentina S; Kiely BE
Intern Med J; 2015 Sep; 45(9):909-15. PubMed ID: 25851689
[TBL] [Abstract][Full Text] [Related]
14. The Role of Physicians in Rationing Cancer Care. Attitudes of German Oncologists.
Fernau S; Mehlis K; Schildmann J; Krause S; Winkler EC
Oncol Res Treat; 2017; 40(9):490-494. PubMed ID: 28813707
[TBL] [Abstract][Full Text] [Related]
15. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.
Schnipper LE; Davidson NE; Wollins DS; Blayney DW; Dicker AP; Ganz PA; Hoverman JR; Langdon R; Lyman GH; Meropol NJ; Mulvey T; Newcomer L; Peppercorn J; Polite B; Raghavan D; Rossi G; Saltz L; Schrag D; Smith TJ; Yu PP; Hudis CA; Vose JM; Schilsky RL
J Clin Oncol; 2016 Aug; 34(24):2925-34. PubMed ID: 27247218
[No Abstract] [Full Text] [Related]
16. Cancer therapy costs influence treatment: a national survey of oncologists.
Neumann PJ; Palmer JA; Nadler E; Fang C; Ubel P
Health Aff (Millwood); 2010; 29(1):196-202. PubMed ID: 20048377
[TBL] [Abstract][Full Text] [Related]
17. Variability in physician opinion on limiting pediatric life support.
Randolph AG; Zollo MB; Egger MJ; Guyatt GH; Nelson RM; Stidham GL
Pediatrics; 1999 Apr; 103(4):e46. PubMed ID: 10103338
[TBL] [Abstract][Full Text] [Related]
18. Weighing up the benefits and harms of a new anti-cancer drug: a survey of Australian oncologists.
Chim L; Salkeld G; Stockler MR; Mileshkin L
Intern Med J; 2015 Aug; 45(8):834-42. PubMed ID: 25950615
[TBL] [Abstract][Full Text] [Related]
19. Oncological resource allocation in Germany.
Hartmann M; Kath R; Gundermann C
Onkologie; 2008 Mar; 31(3):85-9. PubMed ID: 18322410
[TBL] [Abstract][Full Text] [Related]
20. How the Affordable Care Act Has Affected Cancer Care in the United States: Has Value for Cancer Patients Improved?
Schleicher SM; Wood NM; Lee S; Feeley TW
Oncology (Williston Park); 2016 May; 30(5):468-74. PubMed ID: 27188679
[No Abstract] [Full Text] [Related]
[Next] [New Search]
